🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,263 results for “Cancer” Clear

  1. FLUOROURACIL , CAPECITABINE , Folikabi 10 mg/ml oplossing voor injectie/infusie, OXALIPLATIN

    Disc Medicine

    Rectal cancer

    phase 3 small molecule active

    1 trial

  2. FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab

    Summit Therapeutics

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  3. FLUOROURACIL, CAPECITABINE, Zimberelimab, OXALIPLATIN, FLUOROURACIL, CALCIUM FOLINATE, DOMVANALIMAB, NIVOLUMAB, FLUOROURACIL, CAPECITABINE

    Arcus Biosciences

    Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer

    phase 3 small molecule active

    1 trial

  4. FULVESTRANT , EXEMESTANE , ABEMACICLIB

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  5. FUROSEMIDE , DULOXETINE

    Cancer Prevention Pharma (Ireland) Limited

    ER positive HER2 negative breast cancer stages I-II

    phase 3 small molecule active

    1 trial

  6. Farletuzumab

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  7. Femara 2.5 mg film-coated tablets, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Anastrozole 1mg film-coated tablets, Docetaxel Pfizer 10 mg/mL concentrate for solution for infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Exemestane 25 mg Film-coated Tablets, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Cancer Prevention Pharma (Ireland) Limited

    low-grade serous carcinoma of the ovary or peritoneum

    phase 3 small molecule active

    1 trial

  8. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Pharma Mar S.A.

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. Firmonertinib

    ArriVent BioPharma

    Non-Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. Fluzoparib

    China SXT Pharmaceuticals

    Breast Cancer Metastatic

    phase 3 small molecule active

    2 trials

  11. ForeCYTE Breast Aspirator

    ATOSSA THERAPEUTICS, INC.

    Breast Cancer, Preneoplastic Conditions, BRCA

    phase 3 other terminated

    1 trial

  12. Furmonertinib, AFATINIB, OSIMERTINIB, OSIMERTINIB, AFATINIB, AFATINIB

    ArriVent BioPharma

    Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    phase 3 small molecule active

    1 trial

  13. GALLIUM (68GA) CHLORIDE, TILMANOCEPT

    Disc Medicine

    Endometrial cancer, uterine cancer

    phase 3 small molecule active

    1 trial

  14. GEMCI-cell® 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Gemcitabine 1 g Powder for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Carbomedac® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusio

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  15. GEMCITABINE , JNJ-17000139, MITOMYCIN

    Janssen-Cilag International N.V.

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  16. GEMCITABINE , Tecentriq, PEMETREXED , VINORELBINE , CISPLATIN , DOCETAXEL , Tecentriq 1,200 mg concentrate for solution for infusion

    Roche Registration Limited

    Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. GEMCITABINE, INFLIXIMAB, CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, Rilvegostomig

    AstraZeneca AB

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  18. GEMCITABINE, PEGFILGRASTIM, PACLITAXEL ALBUMIN-BOUND, BL-B01D1, CAPECITABINE, CARBOPLATIN, PACLITAXEL, CAPECITABINE

    Bristol-Myers Squibb / Pfizer EEIG

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  19. GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

    Novartis Ophthalmics Europe

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  20. Ga-68-PSMA-11

    Telix Innovations

    Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  21. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Merck Sharp and Dohme

    ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.​

    phase 3 small molecule active

    1 trial

  22. Gefitinib

    China SXT Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  23. Gemcitabine 38 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Gilead Sciences International Limited

    PD-L1 Positive Metastatic Triple-Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  24. HIPEC with neoadjuvant chemotherapy

    China SXT Pharmaceuticals

    Gastric Cancer

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources